On Monday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was 3.23% up from the session before settling in for the closing price of $2.48. A 52-week range for TSHA has been $1.19 – $4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 129.39%. When this article was written, the company’s average yearly earnings per share was at 61.46%. With a float of $153.61 million, this company’s outstanding shares have now reached $204.94 million.
Let’s determine the extent of company efficiency that accounts for 52 employees. In terms of profitability, gross margin is 90.01%, operating margin of -880.73%, and the pretax margin is -229.67%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 25.05%, while institutional ownership is 69.54%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 61.46% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.03, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 4.33 million, which is a jump from its year-to-date volume of 2.83 million. As of the previous 9 days, the stock’s Stochastic %D was 26.61%. Additionally, its Average True Range was 0.27.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 64.62%, which indicates a significant increase from 44.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.77% in the past 14 days, which was higher than the 101.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.10, while its 200-day Moving Average is $2.46. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.69. Second resistance stands at $2.82. The third major resistance level sits at $2.92. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.35. Should the price break the second support level, the third support level stands at $2.22.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 204,943K outstanding shares of the company, which has a market capitalization of 546.70 million. As of now, sales total 15,450 K while income totals -111,570 K. Its latest quarter income was 1,790 K while its last quarter net income were -25,520 K.
